• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Nanoparticles

Nanoparticles use 2 mechanisms to boost immunotherapy

June 12, 2017 By Sarah Faulkner

Nanoparticle immunotherapy

Cancer immunotherapy, a treatment approach that has gained momentum over the past few years, only helps a small fraction of patients. But researchers from the Johns Hopkins University School of Medicine have developed a nanoparticle that may one day help expand the patient population that benefits from immunotherapy. Immunotherapy usually falls into 1 of 2 […]

Filed Under: Featured, Immunotherapy, Nanoparticles, Oncology, Preclinical Trials, Research & Development Tagged With: Johns Hopkins

Magnets, nanoparticles open and close blood vessels for targeted drug delivery

June 9, 2017 By Sarah Faulkner

Magnets for targeted drug delivery - Rice University team

Tightly-packed endothelial cells line blood vessels and maintain a highly structured barrier. But researchers from Rice University, Emory University and the Georgia Institute of Technology have found a way to selectively create “leaky” blood vessels for targeted drug delivery. The team’s study, which was published in Nature Communications, reported that magnets can help lead iron-oxide nanoparticles […]

Filed Under: Drug-Device Combinations, Featured, Nanoparticles, Pharmaceuticals, Research & Development Tagged With: emoryuniversity, Georgia Institute of Technology, Rice University

Novavax touts nanoparticle RSV vaccine in women of child-bearing age

June 7, 2017 By Sarah Faulkner

Novavax

Novavax Inc. (NSDQ:NVAX) touted data today from the second Phase II trial of its RSV F nanoparticle vaccine candidate in women of child-bearing age. The research was published in the journal Vaccine. Novavax’s nanomedicine vaccine is being developed to protect infants from the respiratory syncytial virus. The Gaithersburg, Md.-based company presented top-line data from the Phase […]

Filed Under: Clinical Trials, Featured, Nanoparticles, Wall Street Beat, Women's Health Tagged With: novavax

Nanoparticles: An industry buzzword meets reality

May 31, 2017 By Sarah Faulkner

Young startups backed by nanoparticle tech face a world hurdles before reaching the clinic. It’s been decades since the first innovations with nanotechnology – and experts are asking, “Where are all the drugs?” It’s been more than 20 years since the FDA approved the first nanoparticle drug, Doxil. At the time, nanoparticles were heralded as a […]

Filed Under: Clinical Trials, Drug-Device Combinations, Featured, Nanoparticles, Pharmaceuticals, Preclinical Trials Tagged With: Boehringer Ingelheim Pharmaceuticals, Catalent, Cerulean Pharma Inc., Dicerna Pharmaceuticals, latonatherapeutics

Revive Therapeutics, University of Wisconsin-Madison ink deal for cannabinoid drug delivery tech

May 30, 2017 By Sarah Faulkner

Revive Therapeutics

Revive Therapeutics (OTC:RVVTF) said today that it inked a research agreement with the University of Wisconsin-Madison to develop a drug delivery technology for cannibinoids. The research program, led by Jess Reed, is slated to evaluate chitosan-tannin composite biomaterial as a delivery mechanism for cannabinoids. Therapeutic biomaterials made from a composite of chitosan and tannin include […]

Filed Under: Featured, Nanoparticles, Pain Management, Research & Development Tagged With: revivetherapeutics, University of Wisconsin-Madison

Nano-drug hitchhikes on white blood cells directly to tumor site

May 16, 2017 By Sarah Faulkner

Researchers from Washington State University have developed a way to target drug delivery to a tumor by attaching the therapeutic to white blood cells. The discovery, which the team describes as a 1st of its kind, could help doctors provide more targeted cancer treatment. The researchers attached a nanoscale particle to a white blood cell […]

Filed Under: Featured, Nanoparticles, Oncology, Preclinical Trials, Research & Development Tagged With: washingtonstateuniversity

Researchers use shock waves, nanoparticles to deliver chemo drugs

May 11, 2017 By Sarah Faulkner

Researchers from the University of Turin demonstrated that combining shock waves with nanoparticles can help deliver chemotherapy to tumors in animal models. The team’s work was published in the journal, Endocrine-Related Cancer. Researchers designed the treatment to use extracorporeal shock waves and nanobubbles to more effectively target the cancer drugs to the tumor site. The team […]

Filed Under: Featured, Nanoparticles, Oncology, Pharmaceuticals, Research & Development Tagged With: University of Turin

Study: Nanoparticle shrinks tumor size by 80% in mouse model

May 5, 2017 By Sarah Faulkner

Mayo Clinic

Researchers from the Mayo Clinic have developed a type of cancer-fighting nanoparticle that is designed to shrink breast cancer tumors and prevent recurrence. In a mouse model, the therapy yielded a 70-80% reduction in tumor size and mice treated with the nanoparticles demonstrated resistance to future tumor recurrence a month later. The nanoparticle is coated […]

Filed Under: Featured, Immunotherapy, Nanoparticles, Oncology, Preclinical Trials, Research & Development Tagged With: Mayo Clinic

Kala touts Phase III data for nanoparticle ophthalmic suspension

May 1, 2017 By Sarah Faulkner

Kala Pharmaceuticals

Kala Pharmaceuticals touted data today from a Phase III trial of its nanoparticle formulation of loteprednol etabonate as a treatment for inflammation and pain in cataract surgery patients. The KPI-121 1% suspension met both primary efficacy endpoints and secondary endpoints and was well tolerated by the trial’s participants. The Waltham, Mass.-based company’s KPI-121 uses Kala’s mucus-penetrating […]

Filed Under: Clinical Trials, Featured, Nanoparticles, Optical/Ophthalmic, Surgical Tagged With: Kala Pharmaceuticals

Nanoparticle vaccine triggers immune system to fight multiple cancer types

April 24, 2017 By Sarah Faulkner

Nanoparticle vaccine

Researchers from the University of Texas Southwestern Medical Center have developed a nanoparticle vaccine immunotherapy that fights multiple cancer types, according to a preclinical study published in Nature Nanotechnology.  The nanovaccine, which the team calls a 1st of its kind, is made up of tumor antigens inside of a synthetic polymer nanoparticle. “What is unique about […]

Filed Under: Featured, Nanoparticles, Oncology, Preclinical Trials, Research & Development Tagged With: University of Texas Southwestern Medical Center

  • « Go to Previous Page
  • Page 1
  • Page 2
  • Page 3
  • Page 4
  • Page 5
  • Page 6
  • Interim pages omitted …
  • Page 10
  • Go to Next Page »

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS